Going viral with cancer immunotherapy, Nat Rev Cancer, vol.14, pp.559-567, 2014. ,
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma, J Clin Oncol, 2015. ,
Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial, Ann Surg Oncol, vol.23, pp.4169-4177, 2016. ,
Immune Checkpoint Blockade: A New Paradigm in Treating Advanced Cancer, J Adv Pract Oncol, vol.5, pp.418-431, 2014. ,
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma, J Clin Oncol, vol.34, pp.2619-2626, 2016. ,
Trial Watch:: Oncolytic viruses for cancer therapy, Oncoimmunology, vol.3, 2014. ,
, Editorial Open Access Immunother Open Acc, an open access journal, vol.2, pp.2471-9552
, Immunotherapy (Los Angel), vol.2, p.4, 2016.
, Immunotherapy: Open Access Immu n o th e ra py: Op e n A cc ess ISSN, pp.2471-9552
Trial Watch-Oncolytic viruses and cancer therapy, Oncoimmunology, vol.5, p.1117740, 2016. ,
Trial watch: Oncolytic viruses for cancer therapy, Oncoimmunology, vol.2, p.24612, 2013. ,
Overcoming Barriers in, 2016. ,
, Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade, Viruses, vol.8, p.9
, Oncolytic Viruses and Immune Checkpoint Inhibitors, Citation: Fonteneau JF, vol.2, p.105, 2016.